[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpPZav2K7RtqFJX0Dd3Udgo1Y6VnyEvfZl1C4jSWUni8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":82,"rows":89},"Children's Hospital Los Angeles",[4],147,false,51,6,27098,12,105,[14,16,19,21,23,26,28,31],{"name":15,"count":9},"Pediatric Obesity",{"name":17,"count":18},"Pain",5,{"name":20,"count":18},"Sickle Cell Disease",{"name":22,"count":18},"Medication Adherence",{"name":24,"count":25},"Anxiety",4,{"name":27,"count":25},"Type 2 Diabetes",{"name":29,"count":30},"Brain and Central Nervous System Tumors",3,{"name":32,"count":30},"Type 1 Diabetes",[34,39,44,49,54,59,64,68,73,78],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT04205175","A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab","2022-10","Feiba",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04760275","Fluoxetine vs CBT in Childhood Anxiety Disorders","2025-02-23","Fluoxetine",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05421897","Rapid Administration Pilot for Infusing Dinutuximab","2026-01","Dinutuximab with Chemotherapy",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03426826","The Gut-Brain Study","2026-03","FMT versus placebo",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06023043","Postoperative Steroid Use in Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis Patients","2026-04-01","Dexamethasone",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05218850","The Use of Butyrate Therapy in Pediatric Ulcerative Colitis","2027-06-30","Butyrate",{"nctId":65,"briefTitle":66,"date":62,"intervention":67},"NCT06413368","Maralixibat in Patients With Cystic Fibrosis and Constipation","Maralixibat 9.5 MG\u002FML [Livmarli]",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05469828","Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia","2028-07-01","Crizanlizumab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05929729","Iron Deficiency Anemia (IDA) and the Brain","2028-09-01","Ferric derisomaltose",{"nctId":79,"briefTitle":80,"date":76,"intervention":81},"NCT07103616","Individual Cerebral Hemodynamic Oxygenation Relationships - ICHOR 4","Randomization of Propofol or Dexmedetomidine",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,114,140,158,182,204,231,252,274,295,316,337,359,386,411,440,458,504,530,553,575,607,629,651,673,699,725,743,765,790,817,840,879,897,915,933,957,984,1009,1027,1045,1069,1097,1122,1148,1174,1199,1226,1252,1270,1294,1320,1345,1369,1393,1420,1438,1456,1481],{"intervention":38,"totalTrials":91,"cells":92},1,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":112},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[],{"trials":103,"activeCount":91,"soonestReadout":37},[104],{"nctId":35,"briefTitle":36,"status":105,"phases":106,"primaryCompletion":37,"completion":37,"start":107,"enrollment":108,"conditions":109,"interventions":111},"ACTIVE_NOT_RECRUITING",[87],"2020-07-01",20,[110],"Hemophilia A With Inhibitor",[38],{"trials":113,"activeCount":95},[],{"intervention":77,"totalTrials":91,"cells":115},{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":124,"NA":138},{"trials":117,"activeCount":95},[],{"trials":119,"activeCount":95},[],{"trials":121,"activeCount":95},[],{"trials":123,"activeCount":95},[],{"trials":125,"activeCount":91,"soonestReadout":76},[126],{"nctId":74,"briefTitle":75,"status":127,"phases":128,"primaryCompletion":76,"completion":76,"start":129,"enrollment":130,"conditions":131,"interventions":136},"RECRUITING",[87],"2023-12-07",120,[132,133,134,135],"IDA - Iron Deficiency Anemia","Anemia","Iron Deficiency Anemia","Anemia, Iron Deficiency",[77,137],"NovaFerrum",{"trials":139,"activeCount":95},[],{"intervention":137,"totalTrials":91,"cells":141},{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":156},{"trials":143,"activeCount":95},[],{"trials":145,"activeCount":95},[],{"trials":147,"activeCount":95},[],{"trials":149,"activeCount":95},[],{"trials":151,"activeCount":91,"soonestReadout":76},[152],{"nctId":74,"briefTitle":75,"status":127,"phases":153,"primaryCompletion":76,"completion":76,"start":129,"enrollment":130,"conditions":154,"interventions":155},[87],[132,133,134,135],[77,137],{"trials":157,"activeCount":95},[],{"intervention":58,"totalTrials":91,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":180},{"trials":161,"activeCount":95},[],{"trials":163,"activeCount":95},[],{"trials":165,"activeCount":95},[],{"trials":167,"activeCount":95},[],{"trials":169,"activeCount":91,"soonestReadout":57},[170],{"nctId":55,"briefTitle":56,"status":171,"phases":172,"primaryCompletion":57,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":179},"NOT_YET_RECRUITING",[87],"2028-12-31","2025-11-01",100,[177,178],"Neuromuscular Scoliosis","Adolescent Idiopathic Scoliosis",[58],{"trials":181,"activeCount":95},[],{"intervention":81,"totalTrials":91,"cells":183},{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":192,"NA":202},{"trials":185,"activeCount":95},[],{"trials":187,"activeCount":95},[],{"trials":189,"activeCount":95},[],{"trials":191,"activeCount":95},[],{"trials":193,"activeCount":91,"soonestReadout":76},[194],{"nctId":79,"briefTitle":80,"status":171,"phases":195,"primaryCompletion":76,"completion":76,"start":196,"enrollment":197,"conditions":198,"interventions":201},[87],"2025-09-01",130,[199,200],"Anesthesia; Reaction","Anesthesia",[81],{"trials":203,"activeCount":95},[],{"intervention":205,"totalTrials":91,"cells":206},"Semaglutide 2.4 mg",{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":227,"NA":229},{"trials":208,"activeCount":95},[],{"trials":210,"activeCount":95},[],{"trials":212,"activeCount":95},[],{"trials":214,"activeCount":91,"soonestReadout":219},[215],{"nctId":216,"briefTitle":217,"status":171,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":226},"NCT06934655","Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth",[86],"2030-11-01","2033-11-01","2026-06-01",150,[15,224,225],"Metabolic and Bariatric Surgery","Semaglutide",[205],{"trials":228,"activeCount":95},[],{"trials":230,"activeCount":95},[],{"intervention":67,"totalTrials":91,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":248,"NA":250},{"trials":234,"activeCount":95},[],{"trials":236,"activeCount":95},[],{"trials":238,"activeCount":95},[],{"trials":240,"activeCount":91,"soonestReadout":62},[241],{"nctId":65,"briefTitle":66,"status":127,"phases":242,"primaryCompletion":62,"completion":62,"start":243,"enrollment":108,"conditions":244,"interventions":247},[85,86],"2025-04-09",[245,246],"Constipation Chronic Idiopathic","Cystic Fibrosis",[67],{"trials":249,"activeCount":95},[],{"trials":251,"activeCount":95},[],{"intervention":43,"totalTrials":91,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":270,"NA":272},{"trials":255,"activeCount":95},[],{"trials":257,"activeCount":95},[],{"trials":259,"activeCount":95},[],{"trials":261,"activeCount":91,"soonestReadout":42},[262],{"nctId":40,"briefTitle":41,"status":105,"phases":263,"primaryCompletion":42,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},[86],"2026-07","2021-02-10",316,[268],"Anxiety Disorders",[43],{"trials":271,"activeCount":95},[],{"trials":273,"activeCount":95},[],{"intervention":72,"totalTrials":91,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":277,"activeCount":95},[],{"trials":279,"activeCount":95},[],{"trials":281,"activeCount":91,"soonestReadout":71},[282],{"nctId":69,"briefTitle":70,"status":171,"phases":283,"primaryCompletion":71,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":288},[84,85],"2029-07-01","2024-07-01",30,[20],[72],{"trials":290,"activeCount":95},[],{"trials":292,"activeCount":95},[],{"trials":294,"activeCount":95},[],{"intervention":63,"totalTrials":91,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":298,"activeCount":95},[],{"trials":300,"activeCount":91,"soonestReadout":62},[301],{"nctId":60,"briefTitle":61,"status":127,"phases":302,"primaryCompletion":62,"completion":62,"start":303,"enrollment":304,"conditions":305,"interventions":307},[84],"2022-06-29",10,[306],"Ulcerative Colitis",[63],{"trials":309,"activeCount":95},[],{"trials":311,"activeCount":95},[],{"trials":313,"activeCount":95},[],{"trials":315,"activeCount":95},[],{"intervention":48,"totalTrials":91,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":335},{"trials":319,"activeCount":95},[],{"trials":321,"activeCount":91,"soonestReadout":47},[322],{"nctId":45,"briefTitle":46,"status":105,"phases":323,"primaryCompletion":47,"completion":47,"start":324,"enrollment":325,"conditions":326,"interventions":328},[84],"2022-11-29",11,[327],"Neuroblastoma",[48],{"trials":330,"activeCount":95},[],{"trials":332,"activeCount":95},[],{"trials":334,"activeCount":95},[],{"trials":336,"activeCount":95},[],{"intervention":53,"totalTrials":91,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":357},{"trials":340,"activeCount":95},[],{"trials":342,"activeCount":91,"soonestReadout":52},[343],{"nctId":50,"briefTitle":51,"status":105,"phases":344,"primaryCompletion":52,"completion":345,"start":346,"enrollment":304,"conditions":347,"interventions":350},[84],"2026-06","2019-08-15",[348,349],"Autism Spectrum Disorder (ASD)","Gastro-Intestinal Disorder",[53],{"trials":352,"activeCount":95},[],{"trials":354,"activeCount":95},[],{"trials":356,"activeCount":95},[],{"trials":358,"activeCount":95},[],{"intervention":360,"totalTrials":91,"cells":361},"Nutropin AQ",{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":370,"NA":384},{"trials":363,"activeCount":95},[],{"trials":365,"activeCount":95},[],{"trials":367,"activeCount":95},[],{"trials":369,"activeCount":95},[],{"trials":371,"activeCount":95},[372],{"nctId":373,"briefTitle":374,"status":375,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":108,"conditions":379,"interventions":383},"NCT00140413","Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia","COMPLETED",[87],"2014-02","2004-12",[380,381,382],"Growth Hormone Deficiency","Septo-Optic Dysplasia","Hypopituitarism",[360],{"trials":385,"activeCount":95},[],{"intervention":387,"totalTrials":91,"cells":388},"Recombinant Antithrombin",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":409},{"trials":390,"activeCount":95},[],{"trials":392,"activeCount":95},[],{"trials":394,"activeCount":95},[],{"trials":396,"activeCount":95},[],{"trials":398,"activeCount":95},[399],{"nctId":400,"briefTitle":401,"status":402,"phases":403,"primaryCompletion":404,"completion":404,"start":405,"enrollment":95,"conditions":406,"interventions":408},"NCT01913444","Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO","WITHDRAWN",[87],"2014-10","2013-07",[407],"Neonates on ECMO",[387],{"trials":410,"activeCount":95},[],{"intervention":412,"totalTrials":91,"cells":413},"FVIII",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":438},{"trials":415,"activeCount":95},[],{"trials":417,"activeCount":95},[],{"trials":419,"activeCount":95},[],{"trials":421,"activeCount":95},[],{"trials":423,"activeCount":95},[424],{"nctId":425,"briefTitle":426,"status":427,"phases":428,"primaryCompletion":429,"completion":430,"start":431,"enrollment":432,"conditions":433,"interventions":436},"NCT04621916","Preventing Inhibitor Recurrence Indefinitely","UNKNOWN",[87],"2024-09-20","2025-04-20","2020-09-21",52,[434,435],"Hemophilia A","Immune Tolerance",[412,437],"Emicizumab",{"trials":439,"activeCount":95},[],{"intervention":437,"totalTrials":91,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":456},{"trials":443,"activeCount":95},[],{"trials":445,"activeCount":95},[],{"trials":447,"activeCount":95},[],{"trials":449,"activeCount":95},[],{"trials":451,"activeCount":95},[452],{"nctId":425,"briefTitle":426,"status":427,"phases":453,"primaryCompletion":429,"completion":430,"start":431,"enrollment":432,"conditions":454,"interventions":455},[87],[434,435],[412,437],{"trials":457,"activeCount":95},[],{"intervention":459,"totalTrials":30,"cells":460},"cyclophosphamide",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":489,"PHASE4":500,"NA":502},{"trials":462,"activeCount":95},[],{"trials":464,"activeCount":95},[],{"trials":466,"activeCount":95},[467,478],{"nctId":468,"briefTitle":469,"status":427,"phases":470,"start":471,"conditions":472,"interventions":473},"NCT00025324","Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors",[85],"2000-12",[29],[474,475,459,476,477],"filgrastim","carboplatin","etoposide","thiotepa",{"nctId":479,"briefTitle":480,"status":375,"phases":481,"completion":482,"start":483,"conditions":484,"interventions":485},"NCT00006258","Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma",[85],"2005-01","1997-11",[29],[474,486,459,476,487,488],"cisplatin","methotrexate","vincristine sulfate",{"trials":490,"activeCount":95},[491],{"nctId":492,"briefTitle":493,"status":427,"phases":494,"primaryCompletion":495,"start":496,"enrollment":130,"conditions":497,"interventions":498},"NCT00392886","Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors",[86],"2010-12","2004-03",[29],[475,486,459,476,487,499,477,488],"temozolomide",{"trials":501,"activeCount":95},[],{"trials":503,"activeCount":95},[],{"intervention":476,"totalTrials":30,"cells":505},{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":520,"PHASE4":526,"NA":528},{"trials":507,"activeCount":95},[],{"trials":509,"activeCount":95},[],{"trials":511,"activeCount":95},[512,516],{"nctId":468,"briefTitle":469,"status":427,"phases":513,"start":471,"conditions":514,"interventions":515},[85],[29],[474,475,459,476,477],{"nctId":479,"briefTitle":480,"status":375,"phases":517,"completion":482,"start":483,"conditions":518,"interventions":519},[85],[29],[474,486,459,476,487,488],{"trials":521,"activeCount":95},[522],{"nctId":492,"briefTitle":493,"status":427,"phases":523,"primaryCompletion":495,"start":496,"enrollment":130,"conditions":524,"interventions":525},[86],[29],[475,486,459,476,487,499,477,488],{"trials":527,"activeCount":95},[],{"trials":529,"activeCount":95},[],{"intervention":475,"totalTrials":531,"cells":532},2,{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":543,"PHASE4":549,"NA":551},{"trials":534,"activeCount":95},[],{"trials":536,"activeCount":95},[],{"trials":538,"activeCount":95},[539],{"nctId":468,"briefTitle":469,"status":427,"phases":540,"start":471,"conditions":541,"interventions":542},[85],[29],[474,475,459,476,477],{"trials":544,"activeCount":95},[545],{"nctId":492,"briefTitle":493,"status":427,"phases":546,"primaryCompletion":495,"start":496,"enrollment":130,"conditions":547,"interventions":548},[86],[29],[475,486,459,476,487,499,477,488],{"trials":550,"activeCount":95},[],{"trials":552,"activeCount":95},[],{"intervention":477,"totalTrials":531,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":565,"PHASE4":571,"NA":573},{"trials":556,"activeCount":95},[],{"trials":558,"activeCount":95},[],{"trials":560,"activeCount":95},[561],{"nctId":468,"briefTitle":469,"status":427,"phases":562,"start":471,"conditions":563,"interventions":564},[85],[29],[474,475,459,476,477],{"trials":566,"activeCount":95},[567],{"nctId":492,"briefTitle":493,"status":427,"phases":568,"primaryCompletion":495,"start":496,"enrollment":130,"conditions":569,"interventions":570},[86],[29],[475,486,459,476,487,499,477,488],{"trials":572,"activeCount":95},[],{"trials":574,"activeCount":95},[],{"intervention":576,"totalTrials":531,"cells":577},"Temozolomide",{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":595,"PHASE3":597,"PHASE4":603,"NA":605},{"trials":579,"activeCount":95},[],{"trials":581,"activeCount":95},[582],{"nctId":583,"briefTitle":584,"status":375,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT00993044","A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin",[84],"2013-02","2009-09",13,[590],"Refractory Solid Tumors in Children",[592,593,576,594],"Irinotecan","Vincristine","Bevacizumab",{"trials":596,"activeCount":95},[],{"trials":598,"activeCount":95},[599],{"nctId":492,"briefTitle":493,"status":427,"phases":600,"primaryCompletion":495,"start":496,"enrollment":130,"conditions":601,"interventions":602},[86],[29],[475,486,459,476,487,499,477,488],{"trials":604,"activeCount":95},[],{"trials":606,"activeCount":95},[],{"intervention":486,"totalTrials":531,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":619,"PHASE4":625,"NA":627},{"trials":610,"activeCount":95},[],{"trials":612,"activeCount":95},[],{"trials":614,"activeCount":95},[615],{"nctId":479,"briefTitle":480,"status":375,"phases":616,"completion":482,"start":483,"conditions":617,"interventions":618},[85],[29],[474,486,459,476,487,488],{"trials":620,"activeCount":95},[621],{"nctId":492,"briefTitle":493,"status":427,"phases":622,"primaryCompletion":495,"start":496,"enrollment":130,"conditions":623,"interventions":624},[86],[29],[475,486,459,476,487,499,477,488],{"trials":626,"activeCount":95},[],{"trials":628,"activeCount":95},[],{"intervention":487,"totalTrials":531,"cells":630},{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":641,"PHASE4":647,"NA":649},{"trials":632,"activeCount":95},[],{"trials":634,"activeCount":95},[],{"trials":636,"activeCount":95},[637],{"nctId":479,"briefTitle":480,"status":375,"phases":638,"completion":482,"start":483,"conditions":639,"interventions":640},[85],[29],[474,486,459,476,487,488],{"trials":642,"activeCount":95},[643],{"nctId":492,"briefTitle":493,"status":427,"phases":644,"primaryCompletion":495,"start":496,"enrollment":130,"conditions":645,"interventions":646},[86],[29],[475,486,459,476,487,499,477,488],{"trials":648,"activeCount":95},[],{"trials":650,"activeCount":95},[],{"intervention":488,"totalTrials":531,"cells":652},{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":663,"PHASE4":669,"NA":671},{"trials":654,"activeCount":95},[],{"trials":656,"activeCount":95},[],{"trials":658,"activeCount":95},[659],{"nctId":479,"briefTitle":480,"status":375,"phases":660,"completion":482,"start":483,"conditions":661,"interventions":662},[85],[29],[474,486,459,476,487,488],{"trials":664,"activeCount":95},[665],{"nctId":492,"briefTitle":493,"status":427,"phases":666,"primaryCompletion":495,"start":496,"enrollment":130,"conditions":667,"interventions":668},[86],[29],[475,486,459,476,487,499,477,488],{"trials":670,"activeCount":95},[],{"trials":672,"activeCount":95},[],{"intervention":674,"totalTrials":91,"cells":675},"deferasirox",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":695,"NA":697},{"trials":677,"activeCount":95},[],{"trials":679,"activeCount":95},[],{"trials":681,"activeCount":95},[],{"trials":683,"activeCount":95},[684],{"nctId":685,"briefTitle":686,"status":687,"phases":688,"primaryCompletion":689,"completion":495,"start":690,"enrollment":91,"conditions":691,"interventions":694},"NCT00981370","Clinical Importance of Treating Iron Overload in Sickle Cell Disease","TERMINATED",[86],"2010-10","2009-04",[692,693],"Anemia, Sickle Cell","Transfusion Hemosiderosis",[674],{"trials":696,"activeCount":95},[],{"trials":698,"activeCount":95},[],{"intervention":700,"totalTrials":91,"cells":701},"Nebulized 3% saline",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":721,"NA":723},{"trials":703,"activeCount":95},[],{"trials":705,"activeCount":95},[],{"trials":707,"activeCount":95},[],{"trials":709,"activeCount":95},[710],{"nctId":711,"briefTitle":712,"status":375,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":719},"NCT00619918","Nebulized Hypertonic Saline for Bronchiolitis",[85,86],"2011-05","2008-02",447,[718],"Bronchiolitis",[700,720],"Nebulized 0.9% saline",{"trials":722,"activeCount":95},[],{"trials":724,"activeCount":95},[],{"intervention":720,"totalTrials":91,"cells":726},{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":739,"NA":741},{"trials":728,"activeCount":95},[],{"trials":730,"activeCount":95},[],{"trials":732,"activeCount":95},[],{"trials":734,"activeCount":95},[735],{"nctId":711,"briefTitle":712,"status":375,"phases":736,"primaryCompletion":714,"completion":714,"start":715,"enrollment":716,"conditions":737,"interventions":738},[85,86],[718],[700,720],{"trials":740,"activeCount":95},[],{"trials":742,"activeCount":95},[],{"intervention":474,"totalTrials":531,"cells":744},{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":746,"activeCount":95},[],{"trials":748,"activeCount":95},[],{"trials":750,"activeCount":95},[751,755],{"nctId":468,"briefTitle":469,"status":427,"phases":752,"start":471,"conditions":753,"interventions":754},[85],[29],[474,475,459,476,477],{"nctId":479,"briefTitle":480,"status":375,"phases":756,"completion":482,"start":483,"conditions":757,"interventions":758},[85],[29],[474,486,459,476,487,488],{"trials":760,"activeCount":95},[],{"trials":762,"activeCount":95},[],{"trials":764,"activeCount":95},[],{"intervention":766,"totalTrials":91,"cells":767},"Cepahlexin",{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":769,"activeCount":95},[],{"trials":771,"activeCount":95},[],{"trials":773,"activeCount":95},[774],{"nctId":775,"briefTitle":776,"status":375,"phases":777,"primaryCompletion":778,"completion":778,"start":779,"enrollment":780,"conditions":781,"interventions":783},"NCT00300092","Pediatric Fingertip Injuries:Are Antibiotics Required?",[85],"2004-07","2000-09",146,[782],"Finger Injuries",[766],{"trials":785,"activeCount":95},[],{"trials":787,"activeCount":95},[],{"trials":789,"activeCount":95},[],{"intervention":791,"totalTrials":91,"cells":792},"MEK162",{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":794,"activeCount":95},[],{"trials":796,"activeCount":95},[],{"trials":798,"activeCount":95},[799],{"nctId":800,"briefTitle":801,"status":375,"phases":802,"primaryCompletion":803,"completion":804,"start":805,"enrollment":12,"conditions":806,"interventions":810},"NCT02285439","Study of MEK162 for Children With Low-Grade Gliomas",[84,85],"2022-11-02","2025-08-01","2016-05-04",[807,808,809],"Low-Grade Gliomas","Malignant Neoplasms, Brain","Soft Tissue Neoplasms",[791],{"trials":812,"activeCount":95},[],{"trials":814,"activeCount":95},[],{"trials":816,"activeCount":95},[],{"intervention":818,"totalTrials":91,"cells":819},"sodium nitrite injection, usp",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":821,"activeCount":95},[],{"trials":823,"activeCount":95},[],{"trials":825,"activeCount":95},[826],{"nctId":827,"briefTitle":828,"status":687,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":18,"conditions":832,"interventions":833},"NCT01033227","Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease",[84,85],"2012-06","2009-12",[20],[818],{"trials":835,"activeCount":95},[],{"trials":837,"activeCount":95},[],{"trials":839,"activeCount":95},[],{"intervention":841,"totalTrials":91,"cells":842},"Cyclophosphamide Dose Level 1",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":873,"PHASE4":875,"NA":877},{"trials":844,"activeCount":95},[],{"trials":846,"activeCount":95},[],{"trials":848,"activeCount":95},[849],{"nctId":850,"briefTitle":851,"status":687,"phases":852,"primaryCompletion":853,"completion":377,"start":854,"enrollment":108,"conditions":855,"interventions":869},"NCT02512679","Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells",[85],"2013-09","2007-02",[856,857,858,859,860,861,862,863,864,865,866,867,868],"Stem Cell Transplantation","Bone Marrow Transplantation","Peripheral Blood Stem Cell Transplantation","Allogeneic Transplantation","Genetic Diseases","Thalassemia","Pediatrics","Diamond-Blackfan Anemia","Combined Immune Deficiency","Wiskott-Aldrich Syndrome","Chronic Granulomatous Disease","X-linked Lymphoproliferative Disease","Metabolic Diseases",[841,870,871,872],"Cyclophosphamide Dose Level 2","Cyclophosphamide Dose Level 3","Cyclophosphamide Dose Level 4",{"trials":874,"activeCount":95},[],{"trials":876,"activeCount":95},[],{"trials":878,"activeCount":95},[],{"intervention":870,"totalTrials":91,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":882,"activeCount":95},[],{"trials":884,"activeCount":95},[],{"trials":886,"activeCount":95},[887],{"nctId":850,"briefTitle":851,"status":687,"phases":888,"primaryCompletion":853,"completion":377,"start":854,"enrollment":108,"conditions":889,"interventions":890},[85],[856,857,858,859,860,861,862,863,864,865,866,867,868],[841,870,871,872],{"trials":892,"activeCount":95},[],{"trials":894,"activeCount":95},[],{"trials":896,"activeCount":95},[],{"intervention":871,"totalTrials":91,"cells":898},{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":900,"activeCount":95},[],{"trials":902,"activeCount":95},[],{"trials":904,"activeCount":95},[905],{"nctId":850,"briefTitle":851,"status":687,"phases":906,"primaryCompletion":853,"completion":377,"start":854,"enrollment":108,"conditions":907,"interventions":908},[85],[856,857,858,859,860,861,862,863,864,865,866,867,868],[841,870,871,872],{"trials":910,"activeCount":95},[],{"trials":912,"activeCount":95},[],{"trials":914,"activeCount":95},[],{"intervention":872,"totalTrials":91,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":918,"activeCount":95},[],{"trials":920,"activeCount":95},[],{"trials":922,"activeCount":95},[923],{"nctId":850,"briefTitle":851,"status":687,"phases":924,"primaryCompletion":853,"completion":377,"start":854,"enrollment":108,"conditions":925,"interventions":926},[85],[856,857,858,859,860,861,862,863,864,865,866,867,868],[841,870,871,872],{"trials":928,"activeCount":95},[],{"trials":930,"activeCount":95},[],{"trials":932,"activeCount":95},[],{"intervention":934,"totalTrials":91,"cells":935},"Desogestrel",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":937,"activeCount":95},[],{"trials":939,"activeCount":95},[],{"trials":941,"activeCount":95},[942],{"nctId":943,"briefTitle":944,"status":687,"phases":945,"primaryCompletion":946,"completion":946,"start":947,"enrollment":91,"conditions":948,"interventions":950},"NCT01500473","Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome",[85],"2016-05-11","2012-02",[949],"Congenital Central Hypoventilation Syndrome",[934],{"trials":952,"activeCount":95},[],{"trials":954,"activeCount":95},[],{"trials":956,"activeCount":95},[],{"intervention":958,"totalTrials":91,"cells":959},"FMT",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":961,"activeCount":95},[],{"trials":963,"activeCount":95},[],{"trials":965,"activeCount":95},[966],{"nctId":967,"briefTitle":968,"status":375,"phases":969,"primaryCompletion":970,"completion":971,"start":972,"enrollment":973,"conditions":974,"interventions":977},"NCT03194529","FMT in Pediatric Crohn's Disease",[84,85],"2019-06-30","2019-07-31","2017-10-09",9,[975,976],"Crohn Disease","Pediatric Crohns Disease",[958],{"trials":979,"activeCount":95},[],{"trials":981,"activeCount":95},[],{"trials":983,"activeCount":95},[],{"intervention":985,"totalTrials":91,"cells":986},"Bivalirudin",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":988,"activeCount":95},[],{"trials":990,"activeCount":95},[991],{"nctId":992,"briefTitle":993,"status":375,"phases":994,"primaryCompletion":995,"completion":405,"start":996,"enrollment":997,"conditions":998,"interventions":1000},"NCT00812370","The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids",[84],"2013-01","2008-09",18,[999],"Deep Venous Thrombosis",[985],{"trials":1002,"activeCount":95},[],{"trials":1004,"activeCount":95},[],{"trials":1006,"activeCount":95},[],{"trials":1008,"activeCount":95},[],{"intervention":592,"totalTrials":91,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1019,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1012,"activeCount":95},[],{"trials":1014,"activeCount":95},[1015],{"nctId":583,"briefTitle":584,"status":375,"phases":1016,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":1017,"interventions":1018},[84],[590],[592,593,576,594],{"trials":1020,"activeCount":95},[],{"trials":1022,"activeCount":95},[],{"trials":1024,"activeCount":95},[],{"trials":1026,"activeCount":95},[],{"intervention":593,"totalTrials":91,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1043},{"trials":1030,"activeCount":95},[],{"trials":1032,"activeCount":95},[1033],{"nctId":583,"briefTitle":584,"status":375,"phases":1034,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":1035,"interventions":1036},[84],[590],[592,593,576,594],{"trials":1038,"activeCount":95},[],{"trials":1040,"activeCount":95},[],{"trials":1042,"activeCount":95},[],{"trials":1044,"activeCount":95},[],{"intervention":1046,"totalTrials":91,"cells":1047},"Fecal Microbial Transplant",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1049,"activeCount":95},[],{"trials":1051,"activeCount":95},[1052],{"nctId":1053,"briefTitle":1054,"status":427,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1060},"NCT02291523","The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis",[84],"2023-11","2016-11-01",101,[306],[1046],{"trials":1062,"activeCount":95},[],{"trials":1064,"activeCount":95},[],{"trials":1066,"activeCount":95},[],{"trials":1068,"activeCount":95},[],{"intervention":1070,"totalTrials":91,"cells":1071},"N-Acetylcysteine",{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1089,"PHASE3":1091,"PHASE4":1093,"NA":1095},{"trials":1073,"activeCount":95},[],{"trials":1075,"activeCount":95},[1076],{"nctId":1077,"briefTitle":1078,"status":375,"phases":1079,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":432,"conditions":1083,"interventions":1088},"NCT02094625","NAC to Prevent Cisplatin-induced Hearing Loss",[84],"2020-09","2021-08","2016-03",[1084,1085,1086,1087],"Neuroectodermal Tumors, Primitive","Liver Neoplasms","Osteosarcoma","Other Childhood Cancers Using Cisplatin-based Regimens",[1070],{"trials":1090,"activeCount":95},[],{"trials":1092,"activeCount":95},[],{"trials":1094,"activeCount":95},[],{"trials":1096,"activeCount":95},[],{"intervention":1098,"totalTrials":91,"cells":1099},"Cholecalciferol",{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1101,"activeCount":95},[],{"trials":1103,"activeCount":95},[1104],{"nctId":1105,"briefTitle":1106,"status":375,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1113},"NCT03759262","Ultra-high Dose Vitamin D for HSCT",[84],"2020-05-10","2018-12-10",33,[1112],"Hematopoietic Stem Cell Transplant",[1098],{"trials":1115,"activeCount":95},[],{"trials":1117,"activeCount":95},[],{"trials":1119,"activeCount":95},[],{"trials":1121,"activeCount":95},[],{"intervention":1123,"totalTrials":91,"cells":1124},"Fondaparinux",{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1140,"PHASE3":1142,"PHASE4":1144,"NA":1146},{"trials":1126,"activeCount":95},[],{"trials":1128,"activeCount":95},[1129],{"nctId":1130,"briefTitle":1131,"status":375,"phases":1132,"primaryCompletion":1133,"completion":831,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1139},"NCT00412464","Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis",[84],"2009-06","2006-09",24,[1137,1138],"Thrombosis","Heparin-induced Thrombocytopenia",[1123],{"trials":1141,"activeCount":95},[],{"trials":1143,"activeCount":95},[],{"trials":1145,"activeCount":95},[],{"trials":1147,"activeCount":95},[],{"intervention":594,"totalTrials":531,"cells":1149},{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1158,"PHASE3":1160,"PHASE4":1162,"NA":1164},{"trials":1151,"activeCount":95},[],{"trials":1153,"activeCount":95},[1154],{"nctId":583,"briefTitle":584,"status":375,"phases":1155,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":1156,"interventions":1157},[84],[590],[592,593,576,594],{"trials":1159,"activeCount":95},[],{"trials":1161,"activeCount":95},[],{"trials":1163,"activeCount":95},[],{"trials":1165,"activeCount":95},[1166],{"nctId":1167,"briefTitle":1168,"status":1169,"phases":1170,"conditions":1171,"interventions":1173},"NCT00870636","Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)","NO_LONGER_AVAILABLE",[],[1172],"Retinopathy of Prematurity",[594],{"intervention":1175,"totalTrials":91,"cells":1176},"School-based influenza vaccination program",{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1178,"activeCount":95},[],{"trials":1180,"activeCount":95},[],{"trials":1182,"activeCount":95},[],{"trials":1184,"activeCount":95},[],{"trials":1186,"activeCount":95},[],{"trials":1188,"activeCount":95},[1189],{"nctId":1190,"briefTitle":1191,"status":375,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1198},"NCT00844051","Study to Evaluate Impact of School-based Influenza Vaccination on School Populations",[88],"2011-06","2009-01",4455,[1197],"Influenza",[1175],{"intervention":1200,"totalTrials":91,"cells":1201},"Metformin",{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1203,"activeCount":95},[],{"trials":1205,"activeCount":95},[],{"trials":1207,"activeCount":95},[],{"trials":1209,"activeCount":95},[],{"trials":1211,"activeCount":95},[],{"trials":1213,"activeCount":95},[1214],{"nctId":1215,"briefTitle":1216,"status":687,"phases":1217,"primaryCompletion":1218,"completion":1218,"start":1219,"enrollment":25,"conditions":1220,"interventions":1225},"NCT01486043","Metformin and Transient Hyperglycemia",[88],"2013-05","2011-12",[1221,1222,1223,1224],"Acute Lymphoblastic Leukemia","Hyperglycemia","Insulin Resistance","Diabetes Mellitus",[1200],{"intervention":1227,"totalTrials":91,"cells":1228},"Hydroxyurea",{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1230,"activeCount":95},[],{"trials":1232,"activeCount":95},[],{"trials":1234,"activeCount":95},[],{"trials":1236,"activeCount":95},[],{"trials":1238,"activeCount":95},[],{"trials":1240,"activeCount":95},[1241],{"nctId":1242,"briefTitle":1243,"status":375,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1250},"NCT03715972","Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia",[],"2022-12-31","2018-07-15",165,[861,20,1249],"Healthy Controls",[1227,1251],"Acetazolamide",{"intervention":1251,"totalTrials":91,"cells":1253},{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1260,"PHASE4":1262,"NA":1264},{"trials":1255,"activeCount":95},[],{"trials":1257,"activeCount":95},[],{"trials":1259,"activeCount":95},[],{"trials":1261,"activeCount":95},[],{"trials":1263,"activeCount":95},[],{"trials":1265,"activeCount":95},[1266],{"nctId":1242,"briefTitle":1243,"status":375,"phases":1267,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1268,"interventions":1269},[],[861,20,1249],[1227,1251],{"intervention":1271,"totalTrials":91,"cells":1272},"Omegaven™",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1274,"activeCount":95},[],{"trials":1276,"activeCount":95},[],{"trials":1278,"activeCount":95},[],{"trials":1280,"activeCount":95},[],{"trials":1282,"activeCount":95},[],{"trials":1284,"activeCount":95},[1285],{"nctId":1286,"briefTitle":1287,"status":375,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":996,"enrollment":1290,"conditions":1291,"interventions":1293},"NCT01089426","Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury",[88],"2019-04",90,[1292],"Liver Injury",[1271],{"intervention":1295,"totalTrials":91,"cells":1296},"Midazolam\u002FRanitidine\u002FEsomeprazole",{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1298,"activeCount":95},[],{"trials":1300,"activeCount":95},[],{"trials":1302,"activeCount":95},[],{"trials":1304,"activeCount":95},[],{"trials":1306,"activeCount":95},[],{"trials":1308,"activeCount":95},[1309],{"nctId":1310,"briefTitle":1311,"status":375,"phases":1312,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1319},"NCT01976078","Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents",[],"2015-04-22","2012-09",45,[1317,1318],"Pharmacokinetics","Voriconazole",[1295],{"intervention":1321,"totalTrials":91,"cells":1322},"Campath",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1324,"activeCount":95},[],{"trials":1326,"activeCount":95},[],{"trials":1328,"activeCount":95},[],{"trials":1330,"activeCount":95},[],{"trials":1332,"activeCount":95},[],{"trials":1334,"activeCount":95},[1335],{"nctId":1336,"briefTitle":1337,"status":402,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":95,"conditions":1342,"interventions":1344},"NCT01639573","Campath-1h Phase I\u002FII Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis",[],"2018-08-02","2018-09-02","2011-04",[1343],"Scleroderma",[1321],{"intervention":1346,"totalTrials":91,"cells":1347},"xifaxan",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1354,"PHASE4":1356,"NA":1358},{"trials":1349,"activeCount":95},[],{"trials":1351,"activeCount":95},[],{"trials":1353,"activeCount":95},[],{"trials":1355,"activeCount":95},[],{"trials":1357,"activeCount":95},[],{"trials":1359,"activeCount":95},[1360],{"nctId":1361,"briefTitle":1362,"status":375,"phases":1363,"primaryCompletion":996,"completion":996,"start":854,"enrollment":1364,"conditions":1365,"interventions":1368},"NCT00619970","Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?",[88],115,[1366,1367],"Chronic Abdominal Pain","Small Intestinal Bacterial Overgrowth",[1346],{"intervention":1370,"totalTrials":91,"cells":1371},"Exenatide",{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1373,"activeCount":95},[],{"trials":1375,"activeCount":95},[],{"trials":1377,"activeCount":95},[],{"trials":1379,"activeCount":95},[],{"trials":1381,"activeCount":95},[],{"trials":1383,"activeCount":95},[1384],{"nctId":1385,"briefTitle":1386,"status":375,"phases":1387,"primaryCompletion":1218,"completion":1388,"start":1389,"enrollment":304,"conditions":1390,"interventions":1392},"NCT01444898","Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome",[88],"2013-12","2012-03",[1391],"Prader-Willi Syndrome",[1370],{"intervention":1394,"totalTrials":91,"cells":1395},"Sodium phosphate enema",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1404,"NA":1406},{"trials":1397,"activeCount":95},[],{"trials":1399,"activeCount":95},[],{"trials":1401,"activeCount":95},[],{"trials":1403,"activeCount":95},[],{"trials":1405,"activeCount":95},[],{"trials":1407,"activeCount":95},[1408],{"nctId":1409,"briefTitle":1410,"status":687,"phases":1411,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":1415,"interventions":1417},"NCT01823848","A Trial of Three Types of Enemas Used to Treat Functional Constipation in Children",[88],"2017-12","2013-04",40,[1416],"Functional Constipation",[1394,1418,1419],"Normal saline enema","Mineral oil enema",{"intervention":1418,"totalTrials":91,"cells":1421},{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1423,"activeCount":95},[],{"trials":1425,"activeCount":95},[],{"trials":1427,"activeCount":95},[],{"trials":1429,"activeCount":95},[],{"trials":1431,"activeCount":95},[],{"trials":1433,"activeCount":95},[1434],{"nctId":1409,"briefTitle":1410,"status":687,"phases":1435,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":1436,"interventions":1437},[88],[1416],[1394,1418,1419],{"intervention":1419,"totalTrials":91,"cells":1439},{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1441,"activeCount":95},[],{"trials":1443,"activeCount":95},[],{"trials":1445,"activeCount":95},[],{"trials":1447,"activeCount":95},[],{"trials":1449,"activeCount":95},[],{"trials":1451,"activeCount":95},[1452],{"nctId":1409,"briefTitle":1410,"status":687,"phases":1453,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":1454,"interventions":1455},[88],[1416],[1394,1418,1419],{"intervention":1457,"totalTrials":91,"cells":1458},"Albuterol",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1460,"activeCount":95},[],{"trials":1462,"activeCount":95},[],{"trials":1464,"activeCount":95},[],{"trials":1466,"activeCount":95},[],{"trials":1468,"activeCount":95},[],{"trials":1470,"activeCount":95},[1471],{"nctId":1472,"briefTitle":1473,"status":375,"phases":1474,"primaryCompletion":1475,"completion":1475,"start":1476,"enrollment":1135,"conditions":1477,"interventions":1479},"NCT02802111","Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults",[88],"2017-09","2015-06",[1478],"Oxygen Consumption",[1457,1480],"Levalbuterol",{"intervention":1480,"totalTrials":91,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1491,"NA":1493},{"trials":1484,"activeCount":95},[],{"trials":1486,"activeCount":95},[],{"trials":1488,"activeCount":95},[],{"trials":1490,"activeCount":95},[],{"trials":1492,"activeCount":95},[],{"trials":1494,"activeCount":95},[1495],{"nctId":1472,"briefTitle":1473,"status":375,"phases":1496,"primaryCompletion":1475,"completion":1475,"start":1476,"enrollment":1135,"conditions":1497,"interventions":1498},[88],[1478],[1457,1480]]